Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01351350 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT01351350 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 68 participants.
The verdict
NCT01351350, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
This is a Phase I, open label, dose escalation study of oral administration of MLN0128 in combination with paclitaxel, with/without trastuzumab, in participants with advanced solid malignancies.
Interventions
- DRUG trastuzumab
- DRUG paclitaxel
- DRUG MLN0128
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2011-02-28 |
| Est. Completion | 2017-09-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01351350
The ClinicalTrials.gov registry entry for NCT01351350 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which trastuzumab is the first listed.
NCT01351350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01351350 about?
NCT01351350 is a clinical study titled "Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies". This is a Phase I, open label, dose escalation study of oral administration of MLN0128 in combination with paclitaxel, with/without trastuzumab, in participants with advanced solid malignancies.
What is the current status of trial NCT01351350?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2011-02-28. Estimated completion is 2017-09-15.
What interventions are being tested in trial NCT01351350?
The interventions under investigation include: trastuzumab (DRUG), paclitaxel (DRUG), MLN0128 (DRUG).
Who is sponsoring clinical trial NCT01351350?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.